All patients
subjects at risk
hydroxychloroquine in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results FACCT Trial, 2021 0.69 [0.28; 1.68]
0.69 [0.28 ; 1.68 ] FACCT Trial, 2021 1 0% 254 NA not evaluable deathsdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52]
FACCT Trial, 2021 0.96 [0.44; 2.08]
1.10 [0.58 ; 2.08 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, FACCT Trial, 2021 2 0% 586 moderate not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12]
1.21 [0.69 ; 2.12 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1 0% 332 NA not evaluable clinical improvement (14-day)detailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44]
0.83 [0.47 ; 1.44 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1 0% 448 NA not evaluable clinical improvement (time to event analysis only)detailed results FACCT Trial, 2021 0.85 [0.62; 1.16]
0.85 [0.62 ; 1.16 ] FACCT Trial, 2021 1 0% 254 NA not evaluable hospital dischargedetailed results FACCT Trial, 2021 0.88 [0.64; 1.21]
0.88 [0.64 ; 1.21 ] FACCT Trial, 2021 1 0% 254 NA not evaluable ICU admissiondetailed results FACCT Trial, 2021 1.42 [0.79; 2.55]
1.42 [0.79 ; 2.55 ] FACCT Trial, 2021 1 0% 254 NA not evaluable adverse eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65]
0.88 [0.29 ; 2.65 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1 0% 332 NA not evaluable 0.5 2.0 1.0 relative treatment effect www.metaEvidence.org 2025-03-09 02:59 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 90
- treatments: 657,832
- roots T: 290